Ketorolac Tromethamine

CHEMBL1201124 Phase 4 Zugelassen Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

376.4 g/mol

LogP

—

Phase

4

The tromethamine salt form of ketorolac, a potent NSAID used for short-term treatment of moderate to severe acute pain. It is often used as an alternative to opioids for postoperative pain management.

Molekularmasse

376,4000 g/mol

TPSA

146,00 Å²

Therapeutische Bereiche

Ovarian Cancer Pancreatic Cancer Glaucoma Age-Related Macular Degeneration Pain Management Non-Small Cell Lung Cancer Migraine Deep Vein Thrombosis / Pulmonary Embolism Lymphoma Type 2 Diabetes Hypertension Breast Cancer Gout Chronic Pain

Wirkmechanismus

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission …

2D-Struktur

SVG PNG

Cite this structure

Embed this structure

SMILES

NC(CO)(CO)CO.O=C(c1ccccc1)c1ccc2n1CCC2C(=O)O

InChI

InChI=1S/C15H13NO3.C4H11NO3/c17-14(10-4-2-1-3-5-10)13-7-6-12-11(15(18)19)8-9-16(12)13;5-4(1-6,2-7)3-8/h1-7,11H,8-9H2,(H,18,19);6-8H,1-3,5H2

Molecular Formula

C19H24N2O6

HBD / HBA

5 / 7

Rotierbare Bindungen

6

Schwere Atome

27

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

The tromethamine salt form of ketorolac, a potent NSAID used for short-term treatment of moderate to severe acute pain. It is often used as an alternative to opioids for postoperative pain management.

Binds to mu (μ), kappa (κ), and/or delta (δ) opioid receptors in the central and peripheral nervous system, mimicking endogenous endorphins. Activation of these G-protein-coupled receptors inhibits pain signal transmission and modulates the emotional response to pain.

Yes, Ketorolac Tromethamine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1201124. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 84003. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Suchen Sie patientenfreundliche Informationen?

Ketorolac Tromethamine auf PillFYI

Struktur

Schnelldaten

Formel: C19H24N2O6
Synonyme: 18

Externe Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.